SPDL1 and cancer: According to several studies that have reported the role of soluble checkpoint molecules in the promotion and progression of cancer, downregulating immune activation [18], here we demonstrated that IFNγ, sPDL1 and sCTLA4 play important roles in regulating the response to TKI treatment.